Grifols (NASDAQ:GRFS) Stock Rating Upgraded by Wall Street Zen

Grifols (NASDAQ:GRFS) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Several other research analysts also recently commented on GRFS. Zacks Research downgraded Grifols from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Grifols in a report on Tuesday, August 5th. One research analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $10.30.

Grifols Stock Up 0.1%

Shares of Grifols stock opened at $8.71 on Friday. Grifols has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20. The company’s 50 day moving average is $9.49 and its 200 day moving average is $9.30. The company has a market cap of $5.99 billion, a price-to-earnings ratio of 45.84, a price-to-earnings-growth ratio of 0.32 and a beta of 0.69.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Versant Capital Management Inc lifted its position in shares of Grifols by 39.5% during the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 1,584 shares during the last quarter. Peterson Wealth Services increased its position in shares of Grifols by 385.8% during the third quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 5,787 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 4,604 shares during the period. PNC Financial Services Group Inc. grew its stake in Grifols by 109.8% in the third quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 4,518 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in Grifols during the 2nd quarter worth $95,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.